Merck’s partner on an experimental antibody-drug conjugate has reported a Phase 3 win in first-line lung cancer, and will take the data to Chinese regulatory authorities.
Chengdu-based Kelun-Biotech said that a combination of its ADC …
Plus, news about Bayer’s Kerendia, Eli Lilly’s Ebglyss and Alto Neuroscience: 📈 CytomX’s colorectal cancer data: The biotech tested multiple doses of its antibody-drug conjugate
A maternal care startup offering virtual and in-person care just raised $12 million in new funding after dropping commercial insurers to focus on Medicaid, Endpoints
AstraZeneca’s cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage gastric cancer.
CirCode Biomed, a Chinese startup working on an experimental class of genetic medicines known as circular RNA, has received the FDA’s blessing to begin a
A German study has stoked debate about the merits of screening for prostate cancer, which is lagging behind breast cancer screening in Europe.
Merck’s partner on an experimental antibody-drug conjugate has reported a Phase 3 win in first-line lung cancer, and will take the data to Chinese regulatory authorities.
Chengdu-based Kelun-Biotech said that a combination of its ADC …